Company intelligence / Profile preview

Dynocardia

Newton Center, Massachusetts, United Statesdynocardia.care ↗

Ownership: Private
Employees: ~7
Development stage: Preclinical

Overview

Dynocardia’s ViTrack technology has demonstrated accurate, reliable continuous non-invasive blood pressure measurement in clinical studies against invasive arterial lines. The device is wrist-worn, user-independent, and provides beat-to-beat BP data as well as other vital signs. The company is preparing for FDA submission following successful verification/validation testing. NIH/NHLBI grants have supported its late-stage development.

Therapeutic areas: OtherCardiovascularWomen's Health
Modalities: DeviceNon-pharmacological therapy (continuous non-invasive blood pressure monitoring)
Industry: Physiological Monitoring

Partnerships

NextCorps Luminate NY accelerator program participant

Beyond the preview

Go deeper on Dynocardia.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Dynocardia.

Explore the full profile